Gene · 2977
GUCY1A2: guanylate cyclase 1 soluble subunit alpha 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GUCY1A2: guanylate cyclase 1 soluble subunit alpha 2. Genes, record 2977. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2977
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P33402 | Guanylate cyclase soluble subunit alpha-2 | 732 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 48584 | P33402 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 18409 | P33402 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 18409 | P33402 | Espacenet |
| EP 4491229 A2 | 2025-01-15 | 89 | P33402 | Espacenet |
| WO 2024230934 A1 | 2024-11-14 | 214 | P33402 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 36966 | P33402 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 139937 | P33402 | Espacenet |
| KR 1020210128370 A | 2021-10-26 | 17 | P33402 | Espacenet |
| KR 1020210125457 A | 2021-10-18 | 3 | P33402 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 4811 | P33402 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs16
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATACIGUAT | CHEMBL2107729 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| CINACIGUAT | CHEMBL1236936 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| ISOSORBIDE DINITRATE | CHEMBL6622 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| ISOSORBIDE MONONITRATE | CHEMBL1311 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| METHYLENE BLUE ANHYDROUS | CHEMBL405110 | Soluble guanylate cyclase inhibitor | INHIBITOR | ChEMBL |
| METHYLENE BLUE CATION | CHEMBL191083 | Soluble guanylate cyclase inhibitor | INHIBITOR | ChEMBL |
| NITRIC OXIDE | CHEMBL1200689 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| NITROGLYCERIN | CHEMBL730 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| NITROPRUSSIDE | CHEMBL2097081 | Soluble guanylate cyclase activator | ACTIVATOR | ChEMBL |
| OLINCIGUAT | CHEMBL4297616 | Soluble guanylate cyclase positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
1 to 10 of 16
See all 16 drugsTrials316
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07603037 | SODIUM NITROPRUSSIDE | ClinicalTrials.gov | ||
| NCT07585201 | NITROGLYCERIN | ClinicalTrials.gov | ||
| NCT07444398 | VERICIGUAT | PHASE1 | ClinicalTrials.gov | |
| NCT07431294 | NITROGLYCERIN | PHASE1 | ClinicalTrials.gov | |
| NCT07268638 | PRALICIGUAT | PHASE2 | ClinicalTrials.gov | |
| NCT07214129 | NITROGLYCERIN | ClinicalTrials.gov | ||
| NCT07121634 | ISOSORBIDE MONONITRATE | ClinicalTrials.gov | ||
| NCT07099144 | NITRIC OXIDE | ClinicalTrials.gov | ||
| NCT07047547 | VERICIGUAT | ClinicalTrials.gov | ||
| NCT06950294 | NITRIC OXIDE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 316
See all 316 trialsNIH grants222
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GUCY1A2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 1 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 1 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 1 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 1 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 1 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 1 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 1 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 1 | 2025 |
| P30CA118100 | University of New Mexico Cancer Center Support Grant | 1 | 2025 |
1 to 10 of 222Source NIH's project files
See all 222 nih grantsPapers244
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A single-cell and spatial transcriptomic atlas of human tuberculous constrictive pericardium. | EBioMedicine | 2026 | 41875497 | PubTator, text mining | PubMed |
| Multi-Omics Mechanism of Chronic Gout Arthritis and Discovery of the Thyroid Hormone-AMPK-Taurine Metabolic Axis. | Cells | 2025 | 41511324 | PubTator, text mining | PubMed |
| CXCL8 is essential for cervical cancer cell acquired radioresistance and acts as a promising therapeutic target in cervical cancer. | Sci Rep | 2025 | 40596054 | PubTator, text mining | PubMed |
| Exonic CircGUCY1A2 inhibits pulmonary artery smooth muscle cells phenotypic switching via regulating O-glycosylation of COL3A1 in pulmonary hypertension. | Eur J Pharmacol | 2025 | 39914785 | PubTator, text mining | PubMed |
| Soluble Guanylate Cyclase Dysfunction and Nitric Oxide Pathway in Chronic Rhinosinusitis With Nasal Polyps: Predictive Markers for Postoperative Recurrence. | Am J Rhinol Allergy | 2025 | 39473384 | PubTator, text mining | PubMed |
| Differential quantification of alternative splicing events on spliced pangenome graphs. | PLoS Comput Biol | 2024 | 39652592 | PubTator, text mining | PubMed |
| [Construction and validation of an immune prognostic risk model in oral squamous cell carcinoma]. | Shanghai Kou Qiang Yi Xue | 2024 | 39478389 | PubTator, text mining | PubMed |
| Acting mechanism and clinical significance of hsa_circ_0005927 in the invasion and metastasis of gastric cancer. | J Cancer | 2024 | 38947400 | PubTator, text mining | PubMed |
| Genetic polymorphisms associated with adverse pregnancy outcomes in nulliparas. | Sci Rep | 2024 | 38714721 | PubTator, text mining | PubMed |
| Heterozygous gain of function variant in GUCY1A2 may cause autonomous ovarian hyperfunction. | Eur J Endocrinol | 2024 | 38578777 | PubTator, text mining | PubMed |
1 to 10 of 244
See all 244 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2977
GET https://conductscience.org/api/genes/v1/2977/patents